| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer | Exec VP, Program Team Lead
1 company
Eisele Jeffrey is a Chief Development Officer at Apellis Pharmaceuticals, Inc.. Recent SEC Form 4 filings include 0 buys and 3 sells.
Estimated insider holdings value: $2.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 1,646 | $68.76 | $113,178.96 | -3.0% | +29.3% | +2.3% | |
| Jan 30, 2023 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 883 | $52.76 | $46,587.08 | -1.9% | +57.2% | +25.1% | |
| Jan 23, 2023 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 4,479 | $51.58 | $231,026.82 | -8.6% | +75.4% | +30.8% |